Affymetrix and Luminex Announce Distribution Agreement
News Oct 16, 2015
Affymetrix Inc. and Luminex Corporation have announced a distribution agreement under which eBioscience, a business unit of Affymetrix, will sell Luminex’s MAGPIX®, Luminex® 200™ and FLEXMAP 3D® multiplexed assay platforms in specified countries in the Americas, Asia and Europe.
Affymetrix will sell the Luminex instruments together with ProcartaPlex® multiplexed immunoassays and QuantiGene® Plex multiplexed quantitative gene expression assays, offering complete solutions to customers working in the fields of drug discovery and development, immuno-oncology and translational research.
The agreement will strengthen continued growth and adoption of Affymetrix’ bead-based assay portfolio, which serves markets growing at double-digit rates worldwide, while expanding the Luminex instrument installed base.
The distribution agreement covers the U.S., Canada, Mexico, Brazil and China as well as The Netherlands, Germany, France, U.K., Switzerland, Austria, Belgium, Ireland, Luxembourg and Poland.
“We are pleased to enter into this agreement with Luminex, the leading instrument provider supporting bead-based multiplexed assays,” said Dara Grantham Wright, senior vice president and general manager of the eBioscience business unit at Affymetrix. “This agreement deepens our relationship with Luminex, and will provide our customers an integrated solution to access a best-in-class platform with an ever-expanding, high-quality assay menu.”
“By enabling Affymetrix to offer both Luminex multiplexing instruments and Affymetrix assays, we can further drive accessibility to customers focused on disease-related research around the world,” said Todd Bennett, vice president, global sales and customer operations, Luminex Corporation.
Bennett continued, “We are very pleased to enter into this agreement, and to support Affymetrix in its efforts to bring flexible, high-quality solutions to laboratories working in the fields of drug discovery and development, immuno-oncology and translational research.”
Some worker honeybees detect and remove sick and dead larvae and pupae from their colonies. This hygienic behaviour, which has a strong genetic component, is known to improve the colony's chance of survival. Researchers narrowed in on the "clean" genes that influence this behaviour to understand the evolution of this unique trait.READ MORE
For some of us, they carry the bright blue of our grandfather's eyes. For others they result in the characteristic cleft chin or the familial tendency toward color blindness. In some families, the genetic mutations handed down from generation to generation aren't as benign. And for one family in particular, the mutation results in early-onset Alzheimer's disease.